John Bondo Hansen

Biography

Contera Pharma (www.conterapharma.com) develops new innovative treatments of movement disorders. Our lead project JM-010 is a New Therapeutic Entity based on strong pre-clinical and clinical evidence that is ready for development for treatment of dyskinesia associated Parkinson's disease and other movement disorders. Other projects are in late-pre-clinic for treatment of e.g. tardive dyskinesia. Contera Pharma has been acquired on 24.11.2014 by Korean Bukwang Pharmaceutical that will initiate global development of JM-010. After acquisition Contera has maintain its office in Copenhagen and will be used as Bukwang Pharmaceutical’s local independent entity within Europe to build research partnership with scientists, laboratories, pharmaceutical companies and bio-ventures. On May 1 2015 Contera Pharma in collaboration with Solural Pharma, Denmark, Ernst Moritz Arndt University Greifswald, Germany and Erweka GmbH, Germany has started a project to develop new treatments of morning akinesia associated with Parkinson’s disease (PD). The project is supported by a Eurostar grant. 

Research Interest

 Pharmacy